Answers are grounded in this paper and cite their sources.
The present study is aimed to investigate the single-dosing pharmacokinetics of two pharmaceutical formulations of atorvastatin 40 mg tablet, test (T) sample (Stacor®) and reference (R) sample (Lipitor®) in Bengali subjects. An open-label, randomized-sequence, two-way, two-period crossover study was designed with 24 healthy Bengali male volunteers. Plasma samples collected before and over 0.5-72.0h after a single oral dose per subject. Samples were analyzed by solid phase extraction method and a validated LCMS/MS method. The non-compartmental pharmacokinetic model was used to measure pharmacokinetic parameters of peak plasma concentration (Cmax), time to reach the peak (Tmax), elimination half-life (T1/2), elimination constant (kel), and area under the curve to 72h (AUC0-72) and to infinity (AUC0-∞). The mean ± SD values of pharmacokinetic parameters for the test and reference products with minor variation were Cmax: 27.617 ± 2.632ng/mL and 26.166 ± 2.948ng/mL; tmax: 2.479 ± 0.634h and 2.396 ± 0.589h; AUC0-24: 256.799 ± 54.002ng-h/mL and 271.562 ± 52.318h-ng/mL; AUC0-∞: 289.172 ± 56.431ng-h/mL and 309.975 ± 59.594ng-h/mL; kel: 0.055 ± 0.005h-1 and 0.053 ± 0.006h-1; t1/2: 12.591±1.325h and 13.178 ± 1.555h respectively. No significant differences (p > 0.05) for these parameters in the paired t-test and no period or sequence effect was observed in ANOVA analysis. The point estimates (90% CI) of ln-transformed values of Cmax, AUC0-72, and AUC0-∞ were 0.97238 - 1.04110, 0.99296 - 1.00641 and 0.99113 - 1.00255 respectively which fell within the acceptable range of bioequivalence.
No takes yet. Share an insight, caveat, or question.
Sajal Kumar Saha (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: